SenzaGen AB — Investor Relations & Filings

SenzaGen AB is a life science company specializing in non-animal, in vitro testing for chemical sensitization. The company develops and markets the proprietary GARD® (Genomic Allergen Rapid Detection) platform, which uses genomics and machine learning to provide high-accuracy assessments of skin and respiratory allergens. Its flagship test, GARD®skin, is a globally recognized and OECD-validated method (TG 442E) for identifying skin sensitizers. SenzaGen's portfolio also includes assays for quantitative potency assessment, which helps establish safe exposure levels. The technology is proven effective for complex substances, including UVCBs, formulations, and medical device extracts. SenzaGen offers its testing services and advisory expertise to the chemical, cosmetic, pharmaceutical, and medical device industries, aiming to replace traditional animal testing with more accurate, human-relevant methods.